What Is Fibroinflammatory Disease?

Fibroinflammatory disease is an umbrella term for a group of conditions in which chronic inflammation and excessive scar-tissue formation (fibrosis) occur together, often producing masses or swelling that can look alarmingly like cancer on imaging and physical exam. The most recognized member of this family is IgG4-related disease, a systemic condition that can strike nearly any organ and is thought to have autoimmune roots, though its exact cause remains unclear. These disorders share a common thread: immune cells infiltrate a tissue, trigger ongoing inflammation, and gradually replace normal architecture with dense fibrous tissue. Because the resulting lumps and organ changes so closely mimic malignancy, getting the right diagnosis often takes nearly a year and multiple wrong guesses along the way.

The Common Thread Across Fibroinflammatory Conditions

What ties fibroinflammatory diseases together is not a single organ or a single trigger but a shared tissue pattern: chronic inflammatory cells intermixed with abundant fibrosis. Some conditions in this group affect a single site, while others spread to multiple organs over time. The spectrum includes IgG4-related disease, retroperitoneal fibrosis, fibrosing mediastinitis, Riedel’s thyroiditis, and certain inflammatory pseudotumors, among others. Although these were historically treated as unrelated diagnoses, researchers now recognize that many share overlapping immune mechanisms and, in some cases, the same underlying disease process.

IgG4-related disease (IgG4-RD) has emerged as the prototype. It gets its name from the dense infiltration of IgG4-positive plasma cells found in affected tissues and, in many patients, elevated levels of the IgG4 antibody in the blood.¹ The condition was first clearly described in the context of autoimmune pancreatitis and has since been linked to disease in the bile ducts, kidneys, lungs, salivary glands, tear glands, thyroid, and even the brain.² Its ability to form inflammatory masses in almost any organ and mimic tumors is one of its most clinically dangerous features.³

What Happens Inside the Tissue

Under the microscope, fibroinflammatory lesions share a recognizable set of features. In IgG4-RD specifically, pathologists look for three hallmarks: a dense infiltrate of immune cells (particularly plasma cells and lymphocytes), a distinctive swirling or “storiform” pattern of fibrosis, and a process called obliterative phlebitis, in which inflamed veins become blocked by scar tissue.⁴ These three features together form the backbone of a pathological diagnosis, even when blood tests are ambiguous.

The immune machinery driving this tissue damage is more complex than simply having too many IgG4 antibodies floating around. Research has pointed to T cells, not just B cells, as central players. In one study of IgG4-RD affecting the brain, investigators found that a specific type of memory T cell appeared to sustain the autoimmune process by signaling to immature B cells and recruiting additional immune cells into the tissue.⁵ Separately, work on fibrosis in general has identified a population of macrophages that drives the activation of fibroblasts, the cells responsible for producing scar tissue, through specific molecular signals.⁶ In other words, the inflammation actively instructs the surrounding tissue to scar, creating a self-reinforcing loop.

Where in the Body It Shows Up

One of the most disorienting things about fibroinflammatory disease is that it can appear virtually anywhere. In IgG4-RD, the pancreas is the classic first site: autoimmune pancreatitis was the condition that originally drew medical attention to the broader disease. But the list of affected organs has grown steadily.

Bile ducts: IgG4-related sclerosing cholangitis causes narrowing of the bile ducts and is found in roughly 90 percent of patients who also have autoimmune pancreatitis. About a quarter of these patients have additional organ involvement, such as kidney lesions or retroperitoneal fibrosis.⁷
Salivary and tear glands: Painless swelling of these glands, historically called Mikulicz’s disease, is the most common head-and-neck manifestation. Patients often notice dry mouth, subtle taste changes, or chronic sinus symptoms.⁸
Thyroid: Riedel’s thyroiditis is a rare fibroinflammatory process that replaces normal thyroid tissue with rock-hard fibrous tissue, sometimes extending into surrounding neck structures. It can cause hypothyroidism and low calcium levels and is now considered part of the IgG4-related disease spectrum.⁹ ¹⁰
Chest: In the lungs and mediastinum (the central compartment of the chest), IgG4-RD may account for a portion of inflammatory pseudotumors, certain interstitial lung diseases, and cases of fibrosing mediastinitis that were previously labeled idiopathic.¹¹ Fibrosing mediastinitis itself is a progressive condition in which fibrous tissue encases structures in the chest, sometimes compressing major blood vessels.¹²

The disease can also affect the kidneys (causing tubulointerstitial nephritis), the aorta (periaortitis), the retroperitoneum (retroperitoneal fibrosis), and, less commonly, the breast, prostate, and skin. Individual patients sometimes have disease in only one organ, while others accumulate involvement in several sites over months or years.

Why It Gets Mistaken for Cancer

Fibroinflammatory masses present a genuine diagnostic trap. On CT scans and MRIs, they can look identical to malignant tumors. When they arise in the pancreas, they mimic pancreatic cancer. In the lung, they look like lung cancer. In the breast, they resemble inflammatory breast carcinoma. The term “tumefactive fibroinflammatory lesion” is sometimes used for these growths specifically because they clinically simulate malignancy, even though biopsy reveals them to be entirely benign.¹³ Inflammatory pseudotumors, a related category, have been found in almost every organ system and are notorious for prompting unnecessary surgery when not correctly identified.¹⁴

A cross-sectional survey of patients and physicians in the United States found that a different diagnosis was initially suspected in over 90 percent of IgG4-RD cases. The most common wrong first guesses included pancreatitis, chronic fatigue syndrome, and vasculitis, and the average time from symptom onset to a correct diagnosis was about a year.¹⁵ That delay matters, because ongoing inflammation leads to progressive fibrosis, and scar tissue, once laid down, does not respond well to treatment.

Diagnosis Beyond the Blood Test

Elevated serum IgG4 is the most talked-about blood marker for IgG4-related disease, and it is genuinely useful, but it is far from a slam dunk. A meta-analysis pooling data from multiple studies reported that using a standard cutoff, the blood test picks up roughly 85 to 87 percent of true cases (sensitivity) and correctly rules out about 83 to 93 percent of non-cases (specificity).¹⁶ ¹⁷ That means a meaningful number of patients with confirmed disease have normal IgG4 levels, and some people without the disease have elevated ones. Raising the diagnostic cutoff (for example, requiring the level to be two or three times the upper limit of normal) improves specificity but at the cost of missing more true cases.¹⁸

Because of these limitations, tissue biopsy remains central. The storiform fibrosis, dense plasma-cell infiltrate, and obliterative phlebitis described earlier are the gold standard. But even biopsy can be inconclusive if the sample is small or comes from a site where the characteristic fibrosis pattern is less pronounced.

An emerging imaging approach uses a combination of two PET tracers: one that lights up areas of active inflammation and another that targets activated fibroblasts. This dual-tracer technique can distinguish inflammatory lesions from fibrotic ones, which matters for treatment decisions because inflammation responds to drugs while established scar tissue generally does not.¹⁹ If validated more broadly, this kind of imaging could help doctors decide when aggressive treatment is still worthwhile and when the window has passed.

Treatment and the Relapse Problem

Corticosteroids are the standard first-line treatment, and they work impressively well initially. In IgG4-RD affecting the pancreas and bile ducts, up to 97 percent of patients respond to steroids.²⁰ For retroperitoneal fibrosis specifically, a randomized trial found prednisone more effective than tamoxifen at preventing relapse and recommended it as first-line therapy.²¹

The trouble is what happens afterward. Relapse is common, occurring in about half of patients in one prospective cohort, with bile duct involvement being a strong predictor of flare-ups.²⁰ This creates a difficult cycle: patients improve on steroids, taper off, relapse, and go back on steroids, accumulating side effects over time.

Rituximab, a drug that depletes B cells, has changed the landscape for steroid-resistant or frequently relapsing cases. In an early case series of ten patients who had failed steroids and other immunosuppressants, nine showed striking improvement within a month of rituximab, and all ten were able to stop steroids entirely.²² Beyond simply reducing inflammation, rituximab appears to slow the fibrotic process itself. Research has shown that B-cell depletion reduces markers of fibroblast activation and collagen deposition, and when disease relapses after rituximab wears off, those fibrosis markers climb again.²³ In a larger review of patients with retroperitoneal fibrosis treated with rituximab, all patients who had symptoms like pain improved, and about 84 percent showed shrinkage of their fibrous mass on follow-up imaging.²⁴

Long-Term Outlook and Complications Worth Knowing

Fibroinflammatory disease is not cancer, but it is not harmless either. The same UK cohort that showed a 97 percent steroid response also reported organ dysfunction in the pancreas, liver, kidney, lung, and brain over time. Mortality was about 10 percent during follow-up, roughly double the rate expected in the age- and sex-matched general population. Perhaps more surprisingly, malignancy occurred in about 11 percent of patients around the time of diagnosis, and the overall cancer risk was significantly elevated compared to national averages.²⁰ Whether the disease itself promotes cancer or whether the chronic immune activation and surveillance happening during workup simply catches cancers that would otherwise be found later is still debated.

On the more reassuring side, a smaller single-center cohort study found that active organ involvement dropped substantially over time regardless of which therapy was used, and only about 17 percent of patients accumulated permanent organ damage during observation.²⁵ The key variable appears to be how quickly treatment begins relative to fibrosis. Inflammation caught early can be reversed; established scar tissue cannot.

How Children Differ from Adults

IgG4-related disease was long considered an adult condition, typically presenting around age 50 with a clear male predominance. Pediatric cases exist but look different in several ways. Children do not show the same male dominance, and surface-organ involvement such as eye disease is more common than internal organ disease.²⁶ Children are also more likely to present with systemic symptoms like fever and weight loss, which are quite unusual in adults with this condition. Single-organ disease is the norm in pediatric patients, with roughly 60 to 68 percent of cases limited to one site, compared to about 40 percent in adults.²⁷ These differences mean that diagnostic criteria developed in adults should be applied cautiously to younger patients.

Fibroinflammatory Disease Beyond IgG4

While IgG4-RD dominates the fibroinflammatory conversation, the category is broader. Biliary atresia, a progressive fibroinflammatory disorder of infancy that destroys bile ducts, has no clear connection to IgG4 and is believed to result from environmental triggers hitting a genetically susceptible child.²⁸ Idiopathic pulmonary fibrosis (IPF), though not always grouped under the fibroinflammatory label, shares the core pattern of immune-driven scarring and has been linked to environmental exposures including metal dust, wood dust, air pollution, and smoking.²⁹ Research comparing bronchoalveolar lavage fluid from patients with IPF, sarcoidosis, and systemic-sclerosis-related lung fibrosis has found distinct immune and protein profiles across these diseases, suggesting that even within fibroinflammatory lung conditions, different immune pathways dominate in different settings.³⁰

This heterogeneity is part of what makes the field so challenging. “Fibroinflammatory disease” is not one disease but a pattern that many diseases share. Understanding that pattern has practical value because it explains why a mass in the pancreas, a lump in the eye socket, and a thickened aorta can all turn out to be the same condition, and why treating the inflammation before it becomes scar tissue is the common therapeutic principle across all of them.

New Therapeutic Directions

Beyond rituximab, researchers are exploring targets that address fibrosis more directly. Thyroid eye disease (Graves’ orbitopathy) is one fibroinflammatory condition where new agents are furthest along. Teprotumumab, which blocks a growth factor receptor involved in both inflammation and tissue remodeling, has already demonstrated clinical benefit in reducing the bulging-eye appearance and active inflammation of this condition.³¹ Early-stage work is also targeting interleukin-11 (IL-11), a signaling molecule that is elevated in fibroinflammatory tissues and that appears to activate stromal cells to produce both inflammatory molecules and fibrotic markers. An antibody called LASN01, which blocks the IL-11 receptor, has shown the ability to suppress these effects in preclinical studies.³²

The broader hope is that drugs targeting specific fibrotic pathways could eventually complement or replace steroids, sparing patients the bone loss, weight gain, diabetes risk, and other side effects that come with long-term corticosteroid use. For now, steroids plus rituximab for refractory cases remains the established approach, but the pipeline is more active than it has ever been.

1
Clinical and Experimental Immunology. Immunology of IgG4-related disease
2
PubMed. IgG4-related disease: historical overview and pathology of hematological disorders
3
PubMed Central. IgG4-mediated sclerosing fibroinflammatory disease presenting as inflammatory breast malignancy
4
PubMed. Consensus statement on the pathology of IgG4-related disease
5
EMBO Molecular Medicine. Intrathecal activation of CD8+ memory T cells in IgG4‐related disease of the brain parenchyma
6
PubMed Central. Platelet-instructed SPP1+ macrophages drive myofibroblast activation in fibrosis in a CXCL4-dependent manner
7
Canadian Journal of Gastroenterology and Hepatology. IgG4‐Related Sclerosing Cholangitis: Rarely Diagnosed, but not a Rare Disease
8
PubMed. Head and neck manifestations of IgG4-related disease: current understanding
9
The Journal of Clinical Endocrinology & Metabolism. Riedel’s Thyroiditis: A Clinical Review
10
PubMed. Riedel’s thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum
11
European Respiratory Journal. Pulmonary manifestations of immunoglobulin G4-related sclerosing disease
12
PubMed Central. Fibrosing mediastinitis: when to suspect and how to evaluate?
13
PubMed Central. Tumefactive Fibroinflammatory Lesion: A Diagnostic Dilemma
14
PubMed. Inflammatory pseudotumor: the great mimicker
15
Arthritis & Rheumatology. Diagnostic Journey, Clinical Burden, And Quality Of Life Of Patients With IGg4-Related Disease
16
PubMed Central. Diagnostic performance of serum IgG4 level for IgG4-related disease: a meta-analysis
17
PubMed Central. Diagnostic Value of Serum IgG4 for IgG4-Related Disease: A PRISMA-compliant Systematic Review and Meta-analysis
18
PubMed Central. Diagnostic Performance of Serum IgG4 Levels in Patients With IgG4-Related Disease
19
Annals of the Rheumatic Diseases. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging
20
PubMed Central. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort
21
The Lancet. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis
22
PubMed. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients
23
Annals of the Rheumatic Diseases. B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease
24
PubMed Central. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis
25
PubMed Central. Long-term treatment patterns and outcomes in IgG4-related disease – a retrospective single-center cohort study focusing on rituximab
26
PubMed. Pediatric IgG4-related disease: a descriptive review
27
PubMed Central. IgG4-Related Disease in Childhood: Clinical Presentation, Management, and Diagnostic Challenges
28
Gastroenterology. Evidence From Human and Zebrafish That GPC1 Is a Biliary Atresia Susceptibility Gene
29
PubMed Central. Environmental Causes of Idiopathic Pulmonary Fibrosis
30
PROTEOMICS. Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis
31
PubMed Central. Therapeutic targets for fibro-inflammation in Graves’ orbitopathy
32
Scientific Reports. IL-11 receptor is a novel target for drug development with pharmacological activity in fibro-inflammatory disease